U.S. Markets close in 26 mins

Abbott Labs and Three Additional Medical Equipment Stocks on Our Research Desk’s Radar

Stock Research Monitor: ABMD, ALGN, and AMDA

LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on ABT sign up now at www.wallstequities.com/registration. On Wednesday, May 23, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,425.96, up 0.64%; the Dow Jones Industrial Average edged 0.21% higher, to finish at 24,886.81; and the S&P 500 closed at 2,733.29, up 0.32%. This Thursday morning, WallStEquities.com looks at the performance of these four Medical Appliances & Equipment stocks: Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), Align Technology Inc. (NASDAQ: ALGN), and Amedica Corp. (NASDAQ: AMDA). All you have to do is sign up today for this free limited time offer by clicking the link below.


Abbott Laboratories

On Wednesday, shares in Abbott Park, Illinois headquartered Abbott Laboratories recorded a trading volume of 4.16 million shares. The stock ended the session 0.73% higher at $61.84. The Company's shares have gained 41.58% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 3.06% and 9.01%, respectively. Moreover, shares of Abbott Labs, which discovers, develops, manufactures, and sells health care products worldwide, have a Relative Strength Index (RSI) of 57.96. Get the full research report on ABT for free by clicking below at:



Danvers, Massachusetts headquartered ABIOMED Inc.'s stock closed the day 2.37% higher at $395.52 with a total trading volume of 484,629 shares. The Company's shares have advanced 35.95% in the past month, 49.84% in the previous three months, and 193.54% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 25.54% and 74.81%, respectively. Additionally, shares of ABIOMED, which engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart, have an RSI of 78.60. Free research on ABMD can be accessed at:


Align Technology

Shares in San Jose, California headquartered Align Technology Inc. recorded a trading volume of 1.24 million shares, which was above their three months average volume of 951.22 thousand shares. The stock ended yesterday's trading session 3.47% higher at $308.20. The Company's shares have advanced 28.60% in the past month, 18.68% over the previous three months, and 122.98% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 16.96% and 31.93%, respectively. Furthermore, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intraoral scanners, and computer-aided design and computer-aided manufacturing digital services, have an RSI of 71.93.

On May 22nd, 2018, research firm Stifel reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $320 a share to $350 a share. Sign up today for the free research report on ALGN at:



Salt Lake City, Utah headquartered Amedica Corp.'s stock finished Wednesday's session 5.61% higher at $1.13 with a total trading volume of 1.52 million shares, which was above their three months average volume of 1.04 million shares. The stock is trading below its 50-day moving average by 22.68%. Additionally, shares of Amedica, which develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the US, Europe, and South America, have an RSI of 45.35. Wall St. Equities' research coverage also includes the downloadable free report on AMDA at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities